Impact of Type 2 Diabetes
Diabetes is a chronic, progressive disease. It is characterized by elevated blood glucose levels resulting from defects in the body related to insulin secretion, insulin action, or both.1-3 According to the 2020 CDC National Diabetes Statistics Report, an estimated 34.2 million Americans (about 1 in 10) have diabetes; type 2 diabetes (T2D) accounts for 90% to 95% of cases.4,5 Further, an additional 88million American adults (1 in 3) have prediabetes, increasing their risk for T2D.6
T2D most often develops in people aged over 45 years, but children, teens, and young adults are also developing the disease in increasing numbers.4,5 Patients with diabetes often present with and are at a higher risk for comorbidities such as atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and renal disease.3,7-9 The results of a systematic review of global clinical records from a 10-year period showed that approximately one-third of patients with T2D had cardiovascular disease (CVD) as a comorbidity.10 Further, approximately two-thirds of deaths in people with diabetes are due to CVD, including ischemic heart disease, other forms of heart disease, principally congestive HF, and stroke.11
Additionally, the presence of HF is an independent risk factor for developing diabetes.9 About 12% of patients with T2D have established HF, and approximately 3.3% of patients with T2D develop HF each year.9 Further, the presence and severity of chronic kidney disease (CKD) highlights individuals with a heightened risk for adverse health outcomes, such as HF.12,13 The CDC estimates that approximately 1 in 3 Americans with diabetes may have CKD, with diabetes further accounting for 38% of reported causes of end-stage kidney disease in the United States.14 Further, in patients with diabetes, the presence of albuminuria is an independent risk factor for mortality.15
It is essential that health care providers identify predictors of excess mortality in patients with T2D to optimally target risk-reduction strategies. Patients with T2D would benefit from more aggressive preventive programs to prevent CVD. Programs that set stringent standards are more likely to reduce the incidence of cardiovascular morbidity and mortality.9
Treatment Goals and Guidelines
Treatment goals for T2D center on maintaining a patients quality of life by preventing or delaying associated complications and comorbidities. Treatment goals focus around glycemic control and CVD risk factor management. The American Diabetes Association (ADA) recommends regular patient follow-up and, importantly, a patient-centered approach to optimize treatmentoutcomes.16,17
Lifestyle modifications, including losing weight, increasing physical activity, and adopting a healthy diet, remain first-line strategies for the management of T2D.16,18 However, most patients with T2D are unable to control hyperglycemia with diet and exercise and require pharmacotherapy. Generally, monotherapy with an oral hypoglycemic agent is initiated; however, owing to the progressive nature of the disease, most patients will eventually require combination therapy and ultimately injectable treatments as monotherapy or part of polytherapy.19,20 The ADA states that early combination therapy can be considered in some patients at treatment initiation to extend the time to treatment failure.20 Pharmacologic therapy should take a stepwise approach, taking into account individual patient characteristics and the presence of comorbid diseases andcomplications.20
Prior consensus statements by the ADA and the European Association for the Study of Diabetes focus on efficacy in reducing hyperglycemia, with treatment tolerability and safety being primary factors in glucose-lowering medication selection.16,21 However, an update to treatment recommendations was added to the latest 2020 consensus report. This update is due to new evidence regarding the benefit of specific medications to reduce mortality, HF, and progression of renal disease in the setting of established CVD in patients with T2D.16,20
The ADA has adopted these updates in their 2020 recommendations, Standards of Medical Care: 9. Pharmacologic Approaches to Glycemic Treatment2020 and 10. Cardiovascular Disease and Risk Management2020.17,20 The current ADA T2D treatment guidelines are based on indicators of high risk or established ASCVD, CKD, and HF, with glycated hemoglobin (A1C) target levels also considered (
).20 The ADA has suggested a treatment cascade, initiating with monotherapy treatment (such as metformin) and progressing through dual or triple therapy options depending on patient characteristics and preferences (
).20
T2D Available Drug Treatment Options Per Updated ADA Guidelines
Metformin
The ADA states that metformin is the preferred initial pharmacologic agent for the treatment of T2D and should be started at the time T2D is diagnosed unless there are contraindications.20 However, as stated previously, T2D is a progressive disease and often requires additional therapy with combinations of drugs that have complementary mechanisms of action.22 As such, many patients will require dual combination therapy to achieve their target A1C level.20 Current recommendations are to use a stepwise addition of medications to metformin to maintain A1C at target levels (
).20
DPP4
Dipeptidyl peptidase-4 (DPP4) inhibitors are oral diabetic agents that are placed as an add-on second-line therapy after metformin failure as insulinotropic agents that have no intrinsic hypoglycemia risk.18,23 There are currently four DPP4 inhibitors available in the United States that have been approved by the FDA (
).24-40
All four DPP4 inhibitors appear to have similar efficacy in terms of glucose-lowering ability.40 A notable favorable characteristic of DPP4 inhibitors is their efficacy and safety profile in patients with impaired renal function.23 Further, in phase 3 clinical trials, DPP4 inhibitors have shown good safety and tolerability profiles. The most frequent adverse events (AEs) observed were nasopharyngitis and skin lesions, although 2 studies showed an increased rate of hospitalization due to HF.23,29,41,42 As CVD outcomes and safety are a concern for the T2D patient population, mortality and morbidity associated with therapy options should be considered when making treatment selections.
Several CVD outcomes trials have been completed, comparing DPP4 inhibitors with placebo against the backdrop of standard diabetes care, and the DPP4 inhibitors have been shown to have a neutral effect on CVD outcomes.40,41,43,44 Meta-analyses, however, suggest a possible increased risk of acute HF or hospitalized HF with certain DPP4 inhibitors versus placebo; more research is required to explore these observations.45,46 As DPP4 inhibitors come with the possible heightened risk of negative CVD effects, they are suggested as second-line therapy as an add-on to metformin in patients with T2D who need to control hypoglycemia but have no preexisting CVD.20,23,45
In assessing the cardiovascular safety profiles of antidiabetic drugs, sodium-glucose cotransporter 2 (SGLT2) inhibitor therapies have emerged with robust evidence for reducing the risk of adverse CVD outcomes in people with T2D who have either established CVD or are at risk of developing CVD and HF.8 Additional benefits have also been seen in those at risk of renal decline and progression to CKD.8
SGLT2 Inhibitors
SGLT2 inhibitors are a fast-growing class of diabetes drugs given their convenient oral route of administration, strong A1C efficacy data, observed reductions in body weight, and antihypertensive effects. Importantly, these drugs show similar efficacy from early through late stages of diabetes.47 The FDA has approved four SGLT2 inhibitorbased therapies for use in T2D patients, as they have been shown to convey CVD protective effects and delay the progression of CKD;48-50 clinical trial data are summarized in
and
.48-57 The primary outcomes for all available studies were a combination of composite end points of CVD death, myocardial infarction (MI) or ischemic stroke, and HF or hospitalization due to HF.18,48-50 A reduction in risk of HF, MI, and stroke are the most common CVD benefits noted in SGLT2 inhibitor clinical studies (
and
).48-57 The most common AEs noted in most trials were an increased risk of genital infections in the SGLT2 inhibitor population compared with placebo, although the CANVAS trial also noted a higher incidence of amputations.48-50
Fixed-Dose Treatment Combinations
Although the above treatment options present favorable rationales for the use of each agent, there are current data to support initial combination therapy to more rapidly attain glycemic goals.58,59 Clinical trials have demonstrated that this approach is superior to sequential addition of medications, in terms of extending time to primary and secondary failure and decreasing risk of associatedcomplications.60,61
DPP4 inhibitors and metformin-based fixed-dose combinations are accessible and may safely be used in T2D patients to reach treatment goals (
and
).23,48-57 Fixed-dose combinations of DPP4 and SGLT2 inhibitors can also be used (as dual therapy when metformin is contraindicated or not tolerated, or as triple therapy with metformin) to achieve treatment goals in patients with T2D (
and
).23,48-57 DPP4 and SGLT2 inhibitor combinations have complementary actions that have resulted in additive reductions of glycemic and blood pressure parameters.23,52 Findings of recent clinical trials of triple-therapy combinations with DPP4 and SGLT2 inhibitors have demonstrated significant clinical benefit over the use of each individual component when utilized on a background of metformin (
and
).48-57 A phase 3, randomized, double-blind, parallel-group study by Defronzo et al, examining different treatment combinations of empagliflozin and linagliptin as compared with each ingredient individually, noted more significant reductions in A1C levels from baseline for those patients receiving the combination treatments (P<.001 for all comparisons) (
and
).48-57 Further, SGLT2 inhibitors and metformin-based combinations have demonstrated reductions in glycemia, blood pressure, body weight, and albuminuria in people with diabetes.48,53-55,62 A study by Pratley et al demonstrated that in T2D patients with inadequate glycemic control with metformin, co-administration of ertugliflozin (5 or 15 mg) with sitagliptin (100 mg) provided significantly greater improvements in measures of glycemic control compared with addition of either agent alone (P<.001 for all comparisons).53 Notably, in a phase 3 randomized double-blind, active controlled, parallel group study, patients on a fixed dose treatment of saxagliptin + dapagliflozin + metformin experienced a lower rate of AE compared with those patients on treatments of either saxagliptin or dapagliflozin alone.56
While these results illustrate that a fixed-dose combination treatment can help attain T2D treatment goals, the choice of treatment should be tailored to each individual and their T2D prognosis and comorbidities. For those patients with T2D and no elevated CV risk DPP4 inhibitors, such as sitagliptin, are a safe and effective treatment option and can lead to similar treatment outcomes. A randomized, double-blind, placebo- and active-controlled, parallel group, double-dummy, dose-ranging study by Amin et al demonstrated that a lower dose combination of ertugliflozin (5 mg) plus metformin lead to similar A1C reductions when compared with a higher dose of sitagliptin (100 mg) alone.55 Ultimately a the choice of treatment regimen should be made through an open dialogue taking into consideration patient treatment goals, T2D comorbidities, and patient lifestyle and preferences.
Summary
Despite more than 200 years of research on lifestyle management of diabetes and more than 50 years of comparative-effectiveness research in diabetes, innumerable unanswered questions regarding the management of T2D remain.16 T2D treatment guidelines have evolved to adapt to the larger picture of disease, but T2D still carries a significant burden of illness and unmet need. T2D treatment is further complicated by patient comorbidities and their associated risk factors. Optimizing treatment pathways can help alleviate the burden of disease and reach treatment goals for this patient population.
SGLT2 inhibitors, a new option recommended by the ADA 2020 guidelines either as single agents or in fixed-dose combinations with other treatments, offer patients the option to take advantage of benefits beyond stabilization of A1C levels. SGLT2 inhibitors have shown favorable CVD effects, including a reduction in the risk of hospitalization for HF, predominantly in patients with T2D and established CVD48,49,51; they have also been shown to delay the progression of kidney disease.51
References
Read more here:
Managing Type 2 Diabetes and the Role of Sodium-Glucose Cotransporter 2 Inhibitors - AJMC.com Managed Markets Network
- This 'itchy' symptom is an early sign of diabetes that people often miss; know more about it - The Times of India - February 7th, 2025
- Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024 - ABC News - February 7th, 2025
- Incidence of type 2 diabetes and metabolic syndrome by Occupation 10-Year follow-up of the Gutenberg Health Study - BMC Public Health - February 7th, 2025
- Abbotts Above the Bias Film Reveals Misconceptions Can Impact Diabetes Care - MultiVu - February 7th, 2025
- Q&A: Diabetes care for the aging population in the digital age - Medical Xpress - February 7th, 2025
- The relationship between oxLDL, sLOX-1, PCSK9 and carotid intima-media thickness in patients with prediabetes and type 2 diabetes - Nature.com - February 7th, 2025
- Nanoparticle Therapy has Potential to Reprogram the Immune System in Type 1 Diabetes - Managed Healthcare Executive - February 7th, 2025
- Muscle quality index is correlated with insulin resistance and type 2 diabetes mellitus: a cross-sectional population-based study - BMC Public Health - February 7th, 2025
- Assessing type-2 diabetes risk based on the Indian diabetes risk score among adults aged 45 and above in India - Nature.com - February 7th, 2025
- Single-cell atlas of human pancreatic islet and acinar endothelial cells in health and diabetes - Nature.com - February 7th, 2025
- Sugary Drinks Fuel Millions of Diabetes and CVD Cases - Medscape - February 7th, 2025
- 1 in 5 UK adults estimated to have diabetes in new record high - Euronews - February 7th, 2025
- New, increasingly widely used diabetes medication may have additional health benefits for older adults - Medical Xpress - February 7th, 2025
- Patients using diabetes apps can miss critical alerts. Heres how to make sure youre getting them - Canon City Daily Record - February 7th, 2025
- Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024 - News-Press Now - February 7th, 2025
- Does wearing a continuous glucose monitor help people without diabetes? We asked experts. - Popular Science - February 7th, 2025
- What is prediabetes and what can you do to stop it? - The Independent - February 7th, 2025
- Diabetes symptoms: 6 high blood sugar warning signs that show on hand and feet - India.com - February 7th, 2025
- The #1 Habit for Better Heart Health If You Have Diabetes, According to Experts - EatingWell - February 7th, 2025
- 'Fix Broken Food System!' Government Urged as Study Says 1 in 5 Brits Affected by Diabetes - Men's Health UK - February 7th, 2025
- World Diabetes Day 2024 - World Health Organization (WHO) - December 6th, 2024
- The WHO Global Diabetes Compact - December 6th, 2024
- Diabetes - World Health Organization (WHO) - December 6th, 2024
- Kumamoto University researchers discover groundbreaking antidiabetic compound - EurekAlert - December 6th, 2024
- Med's David Kaelber comments on GLP-1 agonists, which provide benefits like managing diabetes and weight loss - The Daily | Case Western Reserve... - December 6th, 2024
- Jordan Chiles Is On a Mission To Raise Awareness for Early Type 1 Diabetes Screening - Verywell Health - December 6th, 2024
- There's A Tasty Food That May Reduce Your Risk Of Developing Type 2 Diabetes, Study Shows - HuffPost - December 6th, 2024
- Empagliflozin Linked to Lower Risk of Diabetic Retinopathy Progression - Medpage Today - December 6th, 2024
- GLP-1 Medications Associated with Reduced Likelihood of Dementia Compared to Other Diabetic Meds - Epic Research - December 6th, 2024
- Sanders Slams Greed That Led to Surge in Obesity, Diabetes in US - The Well News - December 6th, 2024
- Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments - The Wall Street Journal - December 6th, 2024
- New Study Teases Out Chocolate and Diabetes Connection - Medpage Today - December 6th, 2024
- Diabetes tool turned wellness trend: Is a glucose monitor right for you? - KARE11.com - December 6th, 2024
- Reporter doesnt have diabetes but wore a glucose monitor anyway. Here's what she learned - CNN - December 6th, 2024
- Lilly's Zepbound (tirzepatide) superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% - Investors |... - December 6th, 2024
- I dont have diabetes, but I wore a glucose monitor for six weeks. Heres what I learned about food (and anxiety) - CNN - December 6th, 2024
- Higher niacin levels linked to lower cardiovascular risk, but not in those with diabetes - Healio - December 6th, 2024
- This Type Of Chocolate Could Reduce Type 2 Diabetes Risk By 21% - NDTV - December 6th, 2024
- New Study Links Safer BPA Alternatives to Obesity, Diabetes, and Hormone Disruption - SciTechDaily - December 6th, 2024
- Turns Out Dark Chocolate Has a Health Benefit That's Shockingly GreatAnd Totally Unexpected - Well+Good - December 6th, 2024
- Global report on diabetes - World Health Organization (WHO) - October 22nd, 2024
- Ultra-processed food may be particularly harmful for people with diabetes, scientists warn - The Independent - October 22nd, 2024
- New drugs may be able to treat multiple problems beyond diabetes - The Straits Times - October 22nd, 2024
- Best Fruits for Diabetes (and What To Avoid) - Health Essentials - October 22nd, 2024
- Cutting Sugar May Reduce Your Diabetes, Stroke, and Depression Risk - Healthline - October 22nd, 2024
- Can Diabetes Care Teams Improve Patient Outcomes and Value? - Medscape - October 22nd, 2024
- Oral Semaglutide Reduces MACE Risk in People With Type 2 Diabetes and CVD - MD Magazine - October 22nd, 2024
- High expression of CNOT6L contributes to the negative development of type 2 diabetes - Nature.com - October 22nd, 2024
- Recent Advances and Therapeutic Benefits of Glucagon-Like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic... - October 22nd, 2024
- Dental teams could detect undiagnosed diabetes in more than one million people with new care pathway - Nature.com - October 22nd, 2024
- Groundbreaking Innovations in Diabetes Care: Highlights from the 2024 Diabetes Technology Meeting - Beyond Type 1 - October 22nd, 2024
- COVID-19 linked to type 2 diabetes onset in children - Medical Xpress - October 22nd, 2024
- The effect of adding pancreatin to standard otilinium bromide and simethicone treatment in type 2 diabetes mellitus patients with irritable bowel... - October 22nd, 2024
- Does microdosing Ozempic work? What experts are saying about the diabetes drug also used for weight loss - Medical Xpress - October 22nd, 2024
- The Link between GLP-1 Drugs and Diabetic Retinopathy Is Not So Clear | AAO 2024 - Managed Healthcare Executive - October 22nd, 2024
- The overexpression of human amylin in pancreatic cells facilitate the appearance of amylin aggregates in the kidney contributing to diabetic... - October 22nd, 2024
- RNAO releases updated guidelines for diabetic foot ulcer care - Benefits and Pensions Monitor - October 22nd, 2024
- COVID-19 raises the risk of type 2 diabetes in children, study reveals - News-Medical.Net - October 22nd, 2024
- Semaglutide: What impact does it really have on heart health? - Medical News Today - October 22nd, 2024
- Glucose monitors for diabetes have finally been funded but a chronic workforce shortage will limit the benefits - The Conversation - October 22nd, 2024
- Early vs Late Fast Window: Is One More Effective? - Medscape - September 13th, 2024
- Breakthrough T1D Walk to Cure Type 1 Diabetes - KATU - September 13th, 2024
- Foods That May Increase Kids' Risk of Type 1 Diabetes Revealed - Newsweek - September 13th, 2024
- Beds and Herts patients to be re-tested in diabetes results error - BBC.com - September 13th, 2024
- This common habit increases your diabetes risk by 50%; Heres how to fix it - The Economic Times - September 13th, 2024
- Elevated risk of pre-diabetes and diabetes in people with past history of COVID-19 in northeastern Nigeria - BMC Public Health - September 13th, 2024
- Study links bananas, oats and yoghurt to greater diabetes risk in susceptible children - The Guardian - September 13th, 2024
- Could the Norton research teams studying diabetes and Alzheimer's come up with a cure? - Courier Journal - September 13th, 2024
- Weight loss, better beta-cell function tied to long-term glycemic control with tirzepatide - Healio - September 13th, 2024
- Study finds weekly insulin injections as effective for diabetes as daily shots - UPI News - September 13th, 2024
- Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Heres what the science says - The Conversation - September 13th, 2024
- With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes - PR Newswire - September 13th, 2024
- Dining with Diabetes workshops offered - The Courier-Express - September 13th, 2024
- Researchers uncover connection between two common diabetes drugs with implications for foot ulcer healing - News-Medical.Net - September 13th, 2024
- The menopause can increase your likelihood of developing heart disease, type 2 diabetes and hypertension but exercise can help lower risk - The... - September 13th, 2024
- Artificial pancreas shows promise in people with type 1 diabetes on kidney dialysis - MSN - September 13th, 2024
- How an Indian executive battled flesh-eating disease and diabetes, and won - South China Morning Post - September 13th, 2024
- India brings early Diabetic Retinopathy detection to the last mile with Artificial Intelligence - PR Newswire - September 13th, 2024
- Why this diabetes drug may be the answer to NASA search for radiation protection - Texas Public Radio - September 13th, 2024
- The National Association of Chain Drug Stores and the American Diabetes Association Promote Nutrition Security and its Role in Preventing and Managing... - September 13th, 2024